Table 2.
Summarized results of three tests evaluated.
| Group | n | Rapid test | ELISA1 | WBA2 | ||||
|---|---|---|---|---|---|---|---|---|
| NDO-LID | LID-1 | NDO-BSA | ND-O-LID | LID-1 | ML2044 | ML2028 | ||
| Confirmed patients | ||||||||
| MB | 20 | 95% (19) | 65% (13) | 90% (18) | 95% (19) | 35% (7) | 35% (7) | 40% (8) |
| PB | 11 | 63.6% (7) | 36.4% (4) | 45.5% (5) | 36.4% (4) | 72.7% (8) | 63.6% (7) | 54.5% (6) |
| At risk | ||||||||
| HHC | 42 | 21.4% (9) | 0% (0) | 35.7% (15) | 2.4% (1) | 31.0% (13) | 23.8% (10) | 31.0% (13) |
| Controls | ||||||||
| TB | 11 | 0% (0) | 9.1% (1) | 9.1% (1) | 0% (0) | 0% (0) | 0% (0) | 0% (0) |
| EC | 10 | 10% (1) | 0% (0) | 10% (1) | 10% (1) | 0% (0) | 20% (2) | 10% (1) |
| Combined | 21 | 4.8% (1) | 4.8% (1) | 9.5% (2) | 4.8% (1) | 0% (0) | 9.5% (2) | 4.8% (1) |
1ELISA was determined as positive if mean OD of duplicate wells was >2 × EC mean OD.
2WBA were determined as positive if IFNγ concentration was >50 pg/mL.